The real health benefits of Wegovy: what the evidence actually shows

The common misconception: Wegovy is just a slimming injection

The phrase "weight-loss jab" gets repeated so often that it crowds out everything else. Wegovy is a GLP-1 receptor agonist, which means it mimics a gut hormone involved in appetite signalling, insulin secretion and the regulation of various metabolic processes. Weight reduction is the most visible result, but it is a consequence of changes happening across several body systems, not the whole story.

Regulatory bodies have recognised this. The MHRA has now licensed Wegovy for three distinct purposes in the UK: weight management, cardiovascular risk reduction, and (as of summer 2026) treatment of metabolic dysfunction-associated steatohepatitis, or MASH. A medicine licensed for three separate indications by the same regulator is not simply a slimming aid, that framing is, bluntly, out of date.

Understanding this distinction matters for anyone weighing up their options. The semaglutide health benefits documented in major trials go beyond dress-size changes; they touch some of the most serious drivers of early death in the UK: heart disease, liver disease and the metabolic consequences of excess weight. Exploring those benefits separately is the most useful thing this page can do.

Cardiovascular risk: what the SELECT trial found

The SELECT trial randomised over 17,000 adults with obesity and established cardiovascular disease but without type 2 diabetes. Participants received either semaglutide 2.4mg weekly or placebo for a median of around 34 months. The result, published in the New England Journal of Medicine, was a 20% relative reduction in the composite risk of major adverse cardiovascular events: heart attack, stroke or cardiovascular death.

That finding was substantial enough that the MHRA granted a separate cardiovascular indication for Wegovy, independent of its weight-management licence. In practice, this means a prescriber can consider cardiovascular risk reduction as a reason to prescribe semaglutide in its own right, provided the patient meets the relevant criteria.

Why might this happen? Weight loss itself reduces cardiovascular strain, but researchers observed benefits in blood pressure, lipid profiles and markers of inflammation that may contribute beyond weight reduction alone. The full mechanism continues to be studied. What the trial established firmly is that the health benefits of semaglutide in a high-risk cardiac population are real and clinically meaningful, not hypothetical. You can read more about the broader benefits of semaglutide across different populations.

Liver disease: the MASH indication approved in July 2026

MASH (previously called NASH, non-alcoholic steatohepatitis) is a progressive form of fatty liver disease associated with obesity, type 2 diabetes and metabolic syndrome. Until recently, no medicine held a UK licence specifically for it.

On 3 July 2026, the MHRA granted conditional approval for Wegovy to treat adults with MASH and moderate-to-advanced liver fibrosis, a first for any medicine in this indication in the UK. The approval was based on trial data showing improvements in liver fibrosis scores and reductions in liver inflammation markers. This is a conditional authorisation, meaning continued evidence generation is required, but the regulatory threshold for approval was met.

For people living with obesity who also have liver disease, this represents a meaningful expansion of what semaglutide can offer. It is worth noting that this indication is separate from the weight-management licence; prescribing decisions depend on which indication applies to the individual patient. Our overview of other benefits of Wegovy covers some of the emerging evidence in adjacent areas.

Blood pressure, blood sugar and metabolic markers

Weight loss of 10–20% carries well-documented downstream effects: reductions in systolic blood pressure, improvements in HbA1c (a marker of blood sugar control), better HDL/LDL cholesterol ratios and lower triglycerides. Wegovy trials consistently recorded these changes alongside weight reduction.

For people with prediabetes, this matters. A meaningful proportion of STEP trial participants who had prediabetes at baseline showed blood-sugar levels that returned to the normal range after treatment. This is not a claim that Wegovy prevents or treats type 2 diabetes (that is not its weight-management licence) but the metabolic benefits of sustained weight reduction are real and well-evidenced. The NHS medicines information on semaglutide outlines the licensed indications and what to expect.

There is also growing interest in the relationship between GLP-1 medicines and mental health. Some patients report improvements in mood and reduced compulsive thinking around food. The data here is earlier-stage, but it is an active area of research. A separate page looks at semaglutide's potential mental health benefits in more detail.

If you are thinking about whether Wegovy could be appropriate for your situation, the Wegovy overview at nume covers eligibility, the licensed doses and the consultation process. Cost is also a practical consideration, the Wegovy pricing page sets out what private treatment involves. One thing worth knowing: the timing of your order matters less than you might think. Orders placed by 12pm Monday to Friday are reviewed the same day and dispatched for next-working-day delivery, so there is no need to wait for payday or the start of a new week, your schedule, not ours, sets the pace. If you are also curious about how semaglutide interacts with viagra, that is covered in a dedicated page. When you are ready, starting a free consultation is the practical next step.